Gentian Diagnostics ASA OSL:GENT:
VATNE CAPITAL REDUCES INDIRECT OWNERSHIP IN CO FROM 13.65% TO 0%
Gentian Diagnostics: Vatne Capital Reduces Indirect Ownership
Earlier from Gentian Diagnostics Asa
- Gentian Diagnostics: Serum calprotectin - marker of systemic inflammation and disease activity
- GENT: Q1 saw stable sales, NT-proBNP project termination, and a focus on new growth opportunities
- Gentian Diagnostics: Invitation to presentation of first quarter results
- Gentian Diagnostics Renews Long-Term Partnership With Bühlmann Laboratories